Lung Neoplasms Clinical Trial
Official title:
Pulmonary Ventilation/Perfusion Imaging With SPECT/CT for the Prediction of Postoperative Residual Pulmonary Function in Patients With Primary Lung Cancer: A Multi-center Clinical Study
Lung cancer is one of the most common malignant tumors in the world and with the highest
incidence in China. Surgery is the most effective therapeutic method for primary lung cancer.
Accurate prediction of residual postoperative pulmonary function in patients, especially
those with borderline pulmonary function, is crucial for proper qualification for surgery.
According to the 3rd American College of Chest Physicians(ACCP) evidence-based clinical
practice guideline (2013), both predictive postoperative (ppo) FEV1.0% and ppoDLCO% are
greater than 60% predicted are required as a first standard of lobectomy for patients with
primary lung cancer. And, according to the British Thoracic Society (BTS) guideline, patients
with ppoFEV1.0% and ppoDLco% less than 40% have high a risk for surgery. Pulmonary
ventilation / perfusion SPECT/CT has recently become available for prediction of lung
function, and it can be used to forecast pulmonary function in consideration of the pulmonary
circulation as well as effective residual lung function. Traditionally, prediction of
postoperative lung function was based on planar method in anterior and posterior projections
of lung scintigraphy. However, SPECT/CT enables measurement of ventilation / perfusion uptake
in each lobe of the lungs in a three dimensional way, which may avoid underestimating
ppoFEV1.0% and provide confidence in suggesting lobectomy or pneumonectomy.
This experiment is intended to explore the use of Q.lung, a volume-based software to
semi-quantitatively calculate pulmonary ventilation/perfusion functional uptake and volume by
SPECT/CT. We hope it can get a more accurate prediction of postoperative residual pulmonary
function to provide better management for clinical surgery.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | November 1, 2019 |
Est. primary completion date | November 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 80 Years |
Eligibility |
Inclusion criteria: age 30-80 years old; newly diagnosis of primary lung cancer with
radiological or pathological evidence; SPECT/CT scan was performed before surgery; written
and informed consent with signature before the study. Exclusion criteria: with other tumor in addition to primary lung caner; receive surgery prior to SPECT/CT scan; failed to complete preoperative and postoperative pulmonary function tests; failed to perform scans; pregnancy, lactation, and impaired renal or liver function; poorly controlled diabetes; poor compliance; contrary to the standard operating procedures; not suitable for clinical trials (for example with mental illness); |
Country | Name | City | State |
---|---|---|---|
China | Tongren Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Tongren Hospital | Hebei Medical University Fourth Hospital, Henan Cancer Hospital, RenJi Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Zhengzhou University, West China Hospital, Zhejiang Tumor Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | compare actual postoperative lung function values to predicted values using residual pulmonary lobar volume by SPECT/CT | using pulmonary lobar volume to calculate predicted postoperative pulmonary test values and compare them with actual postoperative values. | 1 month | |
Primary | compare actual postoperative lung function values to predicted values using residual ventilation uptake by SPECT/CT | using ventilation uptake (in counts) to calculate predicted postoperative pulmonary test values and compare them with actual postoperative values. | 1 month | |
Primary | compare actual postoperative lung function values to predicted values using residual perfusion uptake by SPECT/CT | using perfusion uptake (in counts) to calculate predicted postoperative pulmonary test values and compare them with actual postoperative values. | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
Completed |
NCT02106143 -
RejuvenAir™ System Lobectomy Safety and Histology Study
|
N/A | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|
||
Completed |
NCT00069160 -
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
|
Phase 2 |